Restenosis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Restenosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Restenosis - Pipeline Review, H1 2015', provides an overview of the Restenosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Restenosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Restenosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Restenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Restenosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Restenosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Restenosis Overview 7
Therapeutics Development 8
Pipeline Products for Restenosis - Overview 8
Pipeline Products for Restenosis - Comparative Analysis 9
Restenosis - Therapeutics under Development by Companies 10
Restenosis - Therapeutics under Investigation by Universities/Institutes 11
Restenosis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Restenosis - Products under Development by Companies 14
Restenosis - Products under Investigation by Universities/Institutes 15
Restenosis - Companies Involved in Therapeutics Development 16
advanceCor GmbH 16
CSPC Pharmaceutical Group Limited 17
CytoTools AG 18
Resverlogix Corp. 19
Shire Plc 20
Viron Therapeutics, Inc. 21
XBiotech USA, Inc. 22
Restenosis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Annexin A-5 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Antibody Conjugate for Restenosis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
butylphthalide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
COR-3 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CV-18C3 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HMW-02Ak - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HMW-02Ap - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HO-3867 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LDH-DDART - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PVS-10200 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Cardiovascular Diseases - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VAN 10-4 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VT-214 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Restenosis - Recent Pipeline Updates 48
Restenosis - Dormant Projects 49
Restenosis - Discontinued Products 51
Restenosis - Product Development Milestones 52
Featured News & Press Releases 52
Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease 52
Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites 53
Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development for Restenosis, H1 2015 8
Number of Products under Development for Restenosis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Restenosis - Pipeline by advanceCor GmbH, H1 2015 16
Restenosis - Pipeline by CSPC Pharmaceutical Group Limited, H1 2015 17
Restenosis - Pipeline by CytoTools AG, H1 2015 18
Restenosis - Pipeline by Resverlogix Corp., H1 2015 19
Restenosis - Pipeline by Shire Plc, H1 2015 20
Restenosis - Pipeline by Viron Therapeutics, Inc., H1 2015 21
Restenosis - Pipeline by XBiotech USA, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Restenosis Therapeutics - Recent Pipeline Updates, H1 2015 48
Restenosis - Dormant Projects, H1 2015 49
Restenosis - Dormant Projects (Contd..1), H1 2015 50
Restenosis - Discontinued Products, H1 2015 51